The short version
- The Royal Swedish Academy of Sciences awarded the 2026 Nobel Prize in Chemistry to Henri B. Kagan and Kensō Soai for their work on asymmetric organic synthesis.
- Their research elucidates how chemical processes can produce an overwhelming excess of one mirror-image form of a molecule, addressing long-standing questions about biological homochirality.
- These findings have become foundational tools in the pharmaceutical industry, enabling the precise creation of drugs that interact safely and effectively with the body's chiral structures.
The Royal Swedish Academy of Sciences announced on Wednesday that Henri B. Kagan of Paris-Sud University in France and Kensō Soai of Tokyo University of Science in Japan have been awarded the 2026 Nobel Prize in Chemistry. The committee cited their discoveries regarding nonlinear effects and autocatalysis in asymmetric organic synthesis, work that has fundamentally altered how scientists understand and manipulate molecular chirality. Each laureate will receive an equal share of the prize money, totaling approximately 12 million Swedish kronor.
The award highlights a critical property of matter known as chirality, where molecules exist in two forms that are mirror images of each other, similar to left and right hands. While laboratory chemical reactions typically produce equal quantities of both forms, life on Earth is remarkably homochiral. Proteins are constructed almost exclusively from L-amino acids, whereas the sugars forming the backbone of DNA and RNA possess a D-configuration. This biological preference for one handedness over the other has long puzzled researchers seeking to understand the origins of life.
Understanding this molecular asymmetry is not merely an academic exercise; it has profound implications for medicine. Many molecules within the human body, including the proteins that drugs target, are themselves chiral. Consequently, the left-handed and right-handed versions of a pharmaceutical compound can interact with biological systems in drastically different ways. One form may provide therapeutic benefits, while its mirror image could be ineffective or even harmful.
The historical significance of this distinction is underscored by the tragedy of thalidomide in the early 1960s. Thousands of children suffered birth defects after their mothers were prescribed the drug for morning sickness. Subsequent research revealed that the two mirror-image forms of thalidomide had distinct biological effects, with one causing severe developmental issues. This disaster highlighted the urgent need for manufacturers to control which molecular form was produced during synthesis.
Henri B. Kagan made a pivotal contribution in 1986 by discovering that a relatively small imbalance between left- and right-handed forms of a catalyst could generate a significantly larger excess of one mirror-image product. This finding provided a mechanism for amplifying chirality, allowing chemists to steer reactions toward specific molecular configurations rather than producing random mixtures.
Kensō Soai expanded upon this concept by developing a reaction where the molecules produced acted as catalysts for their own creation, a process known as autocatalysis. In 2003, Soai demonstrated a reaction that yielded almost exclusively one mirror-image form. This achievement reproduced the molecular one-handedness characteristic of living organisms for the first time in a laboratory setting, offering potential insights into how biological homochirality might have emerged from prebiotic chemistry.
The impact of these discoveries extends far beyond theoretical biology. The principles established by Kagan and Soai are now embedded in the development of catalysts used across various industries to produce specific molecular forms. Experts note that while it may be difficult to attribute a single drug to this research, the understanding of how catalysts function is ubiquitous in modern pharmaceutical development.
Kensō Soai described receiving the news as one of the most exciting days of his life, expressing pride in an experiment he believes offers a plausible explanation for the origins of life's molecular asymmetry. The Nobel committee emphasized that these insights have reshaped the field, providing essential tools for creating safer and more effective medicines by ensuring that only the desired molecular form is synthesized.
As the scientific community reflects on this achievement, the focus remains on how these fundamental discoveries continue to drive innovation in organic chemistry. The ability to control chirality with precision has become a standard requirement in drug design, reducing risks associated with unintended biological interactions. This recognition underscores the enduring importance of basic research in solving practical problems that affect public health and industrial manufacturing.
The announcement in Stockholm marks a significant moment for the field of asymmetric synthesis, validating decades of work aimed at understanding the subtle forces that dictate molecular shape. By bridging the gap between prebiotic chemistry and modern pharmaceutical engineering, Kagan and Soai have provided a framework that continues to influence how scientists approach the creation of complex organic molecules.
Sources behind this briefing
Go to the original reporting
- The Guardian US↗Nobel prize in chemistry awarded for work on mirror-image molecules
